Asset Details
Do you wish to reserve the book?
Upregulation of CD22 by Chidamide promotes CAR T cells functionality
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Upregulation of CD22 by Chidamide promotes CAR T cells functionality
Do you wish to request the book?
Upregulation of CD22 by Chidamide promotes CAR T cells functionality
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Upregulation of CD22 by Chidamide promotes CAR T cells functionality
2021
Overview
Treatment failure or relapse due to tumor escape caused by reduction in target antigen expression has become a challenge in the field of CART therapy. Target antigen density is closely related to the effectiveness of CART therapy, and reduced or lost target antigen expression limits the efficacy of CART therapy and hinders the durability of CAR T cells. Epigenetic drugs can regulate histones for molecular modifications to regulate the transcriptional, translational and post-translational modification processes of target agents, and we demonstrated for the first time the role in regulating CD22 expression and its effect on the efficacy of CD22 CART. In this paper, we found that Chidamide promoted the expression of CD22 on the surface of B-cell tumor cells in vitro and in vivo, and enhanced the function of CD22 CART. As for mechanisms, we demonstrated that Chidamide did not affect CD22 mRNA transcription, but significantly increased the expression of total CD22 protein, indicating that Chidamide may upregulate cell surface CD22 expression by affecting the distribution of CD22 protein. In summary, our results suggest that Chidamide may enhance the efficacy of CD22 CART by inhibiting histone deacetylases to regulate post-transcriptional modifications that affect protein distribution to increase the expression of CD22 on the cell surface.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 631/67
/ Aminopyridines - pharmacokinetics
/ Antigens
/ Benzamides - pharmacokinetics
/ Cocaine- and amphetamine-regulated transcript protein
/ Gene Expression - drug effects
/ Histone Deacetylase Inhibitors - pharmacology
/ Histones
/ Humanities and Social Sciences
/ Humans
/ Immunotherapy, Adoptive - methods
/ Precursor B-Cell Lymphoblastic Leukemia-Lymphoma - immunology
/ Proteins
/ Receptors, Chimeric Antigen - immunology
/ Science
/ Sialic Acid Binding Ig-like Lectin 2 - drug effects
